Dissonance in the face of Alzheimer's disease breakthroughs: clinician and lay stakeholder acceptance, concerns and willingness to pay for emerging disease-modifying therapies
Irina Kinchin(Trinity College Dublin), Iracema Leroi(Trinity College Dublin), Laura O’Philbin(The Alzheimer Society of Ireland), Sharon Walsh(Ollscoil na Gaillimhe – University of Galway), Seán O’Dowd(Trinity College Dublin), Ann-Marie Miller(St. James's Hospital), Seán Kennelly(Trinity College Dublin), Rachel Dinh(Trinity College Dublin), Suzanne Timmons(University College Cork), Margaret Kapuwa(Trinity College Dublin), Anne Nolan(Trinity College Dublin)
Cited by 7
Related Papers
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial
|The Lancet Neurology|2009|460
Cognitive Impairment in Parkinson Disease
|Journal of Geriatric Psychiatry and Neurology|2012|380
Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's disease
|International Journal of Geriatric Psychiatry|2004|228
Neuropsychiatry of Huntington’s Disease and Other Basal Ganglia Disorders
|Psychosomatics|2000|223
Impact of the COVID-19 Pandemic on Loneliness and Social Isolation: A Multi-Country Study
|International Journal of Environmental Research and Public Health|2021|208